Loading clinical trials...
Loading clinical trials...
A Phase 1 Safety, Tolerability, and Pharmacokinetics & Pharmacodynamics Study of Multiple- Dose BIVV009 in Patients With Chronic Immune Thrombocytopenia (ITP)
Conditions
Interventions
BIVV009 6.5 grams
BIVV009 7.5 grams
Locations
5
United States
Georgetown Lombardi Comprehensive Cancer Center
Georgetown, District of Columbia, United States
Massachusetts General Hospital - Cancer Center
Boston, Massachusetts, United States
University of Pittsburgh Medical Center (UPMC) Hilman Cancer Center
Pittsburgh, Pennsylvania, United States
Essen University Hospital Department of Hematology
Essen, Germany
University College Hospital
London, United Kingdom
Start Date
August 14, 2017
Primary Completion Date
February 16, 2021
Completion Date
February 16, 2021
Last Updated
May 18, 2023
NCT03010202
NCT00547066
NCT00441090
NCT03443570
NCT02334813
NCT01327872
Lead Sponsor
Bioverativ, a Sanofi company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions